
A case of children with high lead levels in China is spotlights a public trust gap
Authorities in the city of Tianshui in China's Gansu province earlier this week said eight people, including the principal of the Heshi Peixin Kindergarten, had been detained after an investigation found 233 students had been exposed to lead after school kitchen staff used inedible paint containing the toxic substance as food coloring.
The case initially generated new outrage in a country long plagued by food and environmental safety scandals.
But in the days since it has also become a lightning rod for public mistrust of official handling of such cases, in a system where there are few independent checks and officials are under pressure to resolve issues quickly.
Among the most glaring examples is the start of the Covid-19 pandemic in central China's Wuhan, when local authorities detained supposed 'rumormongers' who had tried to warn of the spread of a virus in the city as officials downplayed the outbreak.
On social media, many are questioning the credibility of the government report and aspects of the state media coverage. Some discussion appears to have been censored online in China's tightly controlled media environment, though other articles exploring the situation remain active.
One mother in the city, whose child does not attend the school that's been at the center of the official investigation, described to CNN mistrust among local families about the government's findings.
'All the parents think (food is not the actual source of the lead poisoning). But we don't know the exact reasons … how are we supposed to know anything?' the mother, who declined to be identified due to concerns about local government retaliation, told CNN in a phone interview.
'Ordinary folks like us probably have no clue – only the government knows what's really going on,' she said.
CNN has repeatedly tried to contact the Tianshui government for comment and has also reached out to China's State Council Information Office by fax. The government in its Tuesday report said the investigation was on-going and that officials from the National Health Commission and other central government departments had helped with the probe.
Among key concerns raised in online discussion are what reports suggest are serious discrepancies between the results of blood tests conducted in Tianshui and those that came back from hospitals in Xi'an, a city in a neighboring province, where some parents took their children to be tested. The Tianshui test results were never publicly disclosed.
One mother of a student at the kindergarten said a local department in Tianshui told her the blood levels of her child were normal, but a hospital in Xi'an later found her child's blood lead levels were 528 micrograms per liter, according to a report published by China National Radio (CNR). China's official guidelines classify this as 'severe lead poisoning.'
Reports from state-affiliated media found that 70 children who were tested in Xi'an had blood lead levels surpassing the threshold of lead poisoning, with six of those cases exceeding 450 micrograms per liter. A full picture of the results from all the students with abnormal levels was not publicly available.
In the investigation report, local authorities said they had conducted sampling investigations at the kindergarten and three affiliated schools and tested food samples, water, outdoor soil and other supplies and equipment. Two food samples – of cake and a corn roll – at the kindergarten, were found to have lead levels more than 2,000 times the national food safety standard for contamination.
But that didn't quell questions. 'The children only eat three-color jujube steamed cake and corn sausage rolls once or twice a week, how could they be poisoned so seriously?' one mother, who gave her surname Wu, told CNR.
Independent blogs online looking into the case have garnered tens of thousands of views. Some discussion appears to have been censored online in China's tightly controlled media environment, though other articles exploring the situation remain active.
Some of these accounts raised questions including about why the school, which authorities said used the paint to 'attract more enrollment and increase revenue,' wouldn't have just used simple food coloring, which ecommerce sites show is generally cheaper than industrial pigment.
Others raised questions about the credibility of an edited closed-circuit video released by state media alleging to show use of the coloring in the kindergarten's kitchen.
Local concerns were also fueled by memory of a 2006 lead poisoning scandal in the same district of Tianshui. Then, over 200 villagers were found to have high levels of lead in their blood during tests conducted outside Tianshui city, according to a state media commentary on the incident published at the time. The source of that lead poisoning case was never officially disclosed.
The current case has caught the attention of prominent figures in China's online ecosystem, including Hu Xijin, former editor-in-chief of state-affiliated media outlet Global Times.
'Questions about environmental pollution are valid, but those raising such concerns need to maintain objectivity in their analysis and should not treat these associative doubts as urgent alarms to spread in society,' Hu wrote on China's X-like social media platform Weibo on Wednesday.
But, he also added it was 'key for authorities providing ample information to strengthen public trust.'
Professor Stuart Khan, head of the University of Sydney's School of Civil Engineering, told CNN that blood lead level concentrations as high as those cited by state media reports about this case would 'typically require regular exposure for several weeks to months, unless there is a very acute poisoning episode' and that levels can rise progressively with 'continuous environmental exposure.'
Potential sources of contamination, such as food, soil or water, could be ruled out by conducting assessments in the broader community and family members of the children to identify who is predominately affected, said Khan, who is not involved in this case.
Lead poisoning used to be a more widespread issue in China. In 2010, the central government for the first time allocated special funds for heavy metal pollution prevention in response to at least 12 high-profile cases the previous year that left more than 4,000 people with elevated blood lead levels, according to state media.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Scale Hits New High: HNC 2025 Concludes with Resounding Success, Driving a New Wave of Health Industry Upgrades
SHANGHAI, July 18, 2025 /PRNewswire/ -- Jointly organized by the China Chamber of Commerce for Import & Export of Medicines & Health Products and Sinoexpo Informa Markets, the "Healthplex Expo 2025, Natural & Nutraceutical Products China 2025" (HNC 2025) was successfully held from June 24 to 26 at the National Exhibition and Convention Center (Shanghai). The HNC 2025 once again achieved a historic breakthrough in scale, winning high praise from all participants. Held concurrently with Hi & Fi Asia-China, ProPak China & FoodPack China, and Starch Expo, the HNC built a business platform integrating the entire industry chain from upstream ingredient supply to end-product distribution. The total exhibition area exceeded 200,000 sqm, bringing together more than 2,500 exhibitors from around the world. Meanwhile, 93,080 professional buyers from 137 countries and regions attended the shows for business exchange and negotiation — a year-on-year increase of 21.2% — fully showcasing the latest achievements and future directions of the health industry, and highlighting its tremendous vitality and boundless potential. The HNC deeply aggregates global resources and builds an industry ecosystem for collaborative development. This year's HNC not only gathered leading enterprises from across China but also attracted industry leaders from more than 30 countries and regions, including Australia, New Zealand, Italy, South Korea, Japan, Malaysia, the United States, Canada, Singapore, Spain, Norway, etc. National pavilions and exhibitors from Italy, Spain, Slovenia, the United States, and Japan made their debuts in China at the exhibition. Local delegations from across China also demonstrated their regional strengths — for example, Jilin pavilion featured its renowned ginseng and antler products, while Xizang pavilion presented its unique highland resources and premium wellness treasures. Both domestic and international exhibitors displayed a diverse range of products and solutions spanning nutritional and health supplements, imported dietary supplements, traditional tonic foods, health foods and beverages, anti-aging beauty products, emotional healing solutions, weight management products, healthcare devices and equipment, as well as third-party professional services. As a vital platform for information exchange, product launches, technology discussions, and market expansion in the health industry, HNC continues to attract a growing number of domestic and international companies, driving deeper collaboration and development across the global health and nutrition sector. Staying true to the innovative spirit of HNC, the exhibition spotlighted trending topics such as sports nutrition, aromatherapy, health foods and beverages, and the medicine and food homology, and curated several themed zones. Highlights included the brand-new "Hi Energy Camp", "Healing Workshop", "Light Wellness Awakening • Food & Beverage Festival", as well as the fully upgraded "TCM Nutrition Zone." These zones combined product showcases, competitions, and immersive experiences, while also collaborating for the first time with Douyin E-Commerce, the leading interest-based e-commerce platform, to offer brands live-streaming sales channels. This cross-ecosystem partnership empowered multiple brands to drive GMV growth and create best-selling products, putting innovative practice into action to boost domestic health consumption and reshape the health ecosystem through category evolution. All activities received enthusiastic feedback from onsite participants. As an industry hub for insights and exchange, the HNC 2025 also hosted more than 50 high-caliber industry events, reaching a new high in scale. The agenda covered professional industry conferences and forums, new product launches, international brand exchanges, innovative interactive experiences, business matchmaking, etc. Hot topics included weight management, applications of medicine and food homology, probiotic research, regulations and market trends for foods for special medical purposes (FSMPs), development of low-GI and whole-grain products, brand building and marketing strategies, hit product incubation, cross-border e-commerce strategies, nutrition across the life cycle, etc. Major events included the 14th Nutraceutical Industry Development Conference (NIDC), The 19th Innovation Hub for Nutrition and Health Food, The 2nd Jilin's Changbai Mountain Ginseng Health (Shanghai) Forum & Related Industry Economic and Trade Matchmaking, 2025 Industry Forum on Medicine and Food Homology, NutriGlobal 2025: Private Advisory Forum for Supply Chain Innovation in China's Health Market, among others. These sessions, held in both Chinese and bilingual formats, gathered government officials, industry association leaders, research experts, and business executives, who shared forward-looking insights and engaged in in-depth exchanges with attendees onsite. Meanwhile, to enhance the efficiency and precision of connections between exhibitors and channel partners, the HNC meticulously organized five targeted business matchmaking sessions onsite. Well-known MCN agencies were specially invited, along with top e-commerce influencers and leading private-domain group leaders, to source new products. Major offline supermarket chains and pharmacy chains also actively participated in the matchmaking sessions. Through this kind of business matchmaking model, broader and more diversified market channels are opened up for exhibitors. To enrich the overall experience for visitors, the HNC significantly upgraded its "Discovery Tour" interactive activity, carefully planning three themed tour routes: Beauty & Anti-Aging, Weight Management, and Tonic Food. Visitors showed great enthusiasm by checking in at booths to learn about the latest products and solutions under each theme. In addition, the HNC launched an all-new immersive cultural experience project called "Trendy Herbal Shop", showcasing the integration of food-medicine homology traditions, as well as a limited-time "Seal-Collecting Tour" activity, which added vibrant fun and cultural depth to the exhibition. The HNC 2025 in Shanghai has come to a successful close. The organizers would like to extend our heartfelt thanks to all exhibitors, professional visitors, partners, and media friends for their invaluable support and enthusiastic participation. Looking ahead, the next stop for HNC will be the "Healthplex Expo, Natural & Nutraceutical Products Shenzhen 2025" (HNC Shenzhen 2025), taking place from December 16 to 18, 2025, at the Shenzhen World Exhibition & Convention Center. Next year at the "Healthplex Expo 2026, Natural & Nutraceutical Products China 2026" (HNC 2026) in Shanghai, we expect to see you again from June 15th to 17th, 2026. We look forward to reuniting with colleagues from the global health and nutrition industry to share the grand occasions, and to jointly write an even more brilliant new chapter for the health industry. CONTACT USSINOEXPO INFORMA MARKETSEmail: HNCEXPO on Facebook / LinkedIn / X View original content: SOURCE Sinoexpo Informa Markets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Fox News
6 hours ago
- Fox News
PAM BONDI & ROBERT MURPHY: Team Trump is fighting deadly drug cartels to save American lives
The Department of Justice (DOJ) and its Drug Enforcement Administration (DEA) are dedicated to upholding the rule of law and championing the safety of the American people against deadly, illegal drugs. No drug continues to pose a greater threat to our nation than fentanyl — a synthetic opioid so powerful, deadly and pervasive that it is the leading cause of death for Americans aged 18 to 45. But we cannot ignore the growing supply of highly addictive and dangerous methamphetamine. The Mexican cartels have created a vast global supply chain, sourcing precursor chemicals from countries like China, manufacturing fentanyl and methamphetamine in secret labs in Mexico, and smuggling them across the border into the United States. These drugs are flooding our communities, and their impact is catastrophic. Current CDC data estimates that 82,000 Americans died from drug overdoses last year — nearly 49,000 from fentanyl and more than 30,000 from psychostimulants, including meth. While we've seen a decline in overdose deaths in recent months, we cannot ignore the threat of fentanyl, often found in other drugs and fake pills. The cartels are also producing methamphetamine pills made to look like Adderall or MDMA, drugs popular with young adults. Fentanyl and methamphetamine together are toxic evidence that the cartels have no value for human life. DEA's mission is clear, and it is confronting this crisis head on. DEA is second to none at developing, interpreting and acting on intelligence. In full coordination, the DOJ is fully committed to prosecuting criminals who are in possession of these dangerous and deadly drugs — including any fentanyl-related substance — to the fullest extent of the law. Under President Donald J. Trump's leadership, the DOJ and the DEA are executing Operation Take Back America, an aggressive campaign to dismantle the criminal organizations responsible for trafficking fentanyl and other synthetic opioids — an unprecedented move to take back our communities and save American lives. Since January 20, DEA has seized over 44 million fentanyl pills and 4,500 pounds of fentanyl powder, representing over 180 million lethal doses and over 68,000 pounds of methamphetamine. Every seizure is a life saved. Every arrest removes a trafficker from the chain of distribution. Every operation sends a message: the United States will not tolerate this attack on its citizens. Our campaign is lawful, methodical and relentless. The DEA operates under a robust framework of legal authorities designed to confront the full spectrum of drug-related crimes. Title 21 authorizes the federal prosecution of drug manufacturers and distributors. RICO statutes allow us to dismantle criminal enterprises. Asset forfeiture laws allow us to strip traffickers of the financial lifeblood of their operations. International extradition agreements ensure that no foreign-based trafficker is beyond the reach of American justice. Each tool is used in coordination with U.S. Attorneys' Offices, in full compliance with constitutional protections and federal evidentiary standards. To name just a few of the recent fentanyl and methamphetamine seizures in the country: Our campaign is lawful, methodical and relentless. The DEA operates under a robust framework of legal authorities designed to confront the full spectrum of drug-related crimes. Each of these operations highlights the critical need to continue attacking the drug supply chain at every level. Our strategy is not limited to arrests and seizures. On July 16, Trump signed the HALT Fentanyl Act into law, which will strengthen penalties for fentanyl dealers and prevent chemists from creating new synthetic compounds to circumvent prosecution. Under Trump's direction, the administration has revitalized interagency coordination. The DOJ and the DEA are working shoulder-to-shoulder with the United States Customs and Border Protection, Homeland Security Investigations, the Federal Bureau of Investigation, Bureau of Alcohol, Tobacco, Firearms and Explosives and federal prosecutors to ensure unified case development from interdiction to indictment. The president has also authorized the use of diplomatic pressure, economic sanctions and trade penalties to hold foreign nations accountable for the chemicals fueling this crisis. The DOJ is also prioritizing enhanced penalties for trafficking offenses involving serious bodily injury or death. We are prosecuting not just the dealers but the enablers, those who launder money, provide logistical support, or serve as brokers between chemical suppliers and cartels. If you profit from this poison, you will face the full force of American justice. As a result of Trump's designation of eight major cartels as Foreign Terrorist Organizations, we are now deploying new tools and charging traffickers with material support to terrorism, a charge that carries up to life in prison. Lining the walls at DEA Headquarters in Arlington, Virginia, are thousands of faces of those lost to fentanyl. These faces are a stark reminder of why we do this work. Each name, each story fuels our resolve to eliminate these cartels and criminal networks and protect our communities. President Trump has made it abundantly clear: the sovereignty of our nation begins with secure borders and safe communities. The era of open borders and drugs flowing across them is over. The federal government is back on offense. Our strategy is not limited to arrests and seizures. On July 16, Trump signed the HALT Fentanyl Act into law, which will strengthen penalties for fentanyl dealers and prevent chemists from creating new synthetic compounds to circumvent prosecution. The American people deserve a justice system that protects their families from the violence of drug trafficking and the horror of overdose death. That is what the DEA and DOJ are delivering. We will not rest until the cartels are crippled, their supply chain is broken and this epidemic has ended. This is a fight for our country, and we intend to win it. Robert Murphy is the acting administrator of the U.S. Drug Enforcement Administration, leading a workforce of nearly 9,000 public servants whose important work protects Americans from the dangers and violence associated with drug trafficking.
Yahoo
6 hours ago
- Yahoo
Abbott Laboratories (ABT) Q2 2025 Earnings Call Highlights: Strong Growth in Medical Devices ...
Sales Growth: 6.9% increase; 7.5% excluding COVID testing sales. Adjusted Earnings Per Share (EPS): $1.26, 11% growth compared to prior year. Gross Margin: 57% of sales, 100 basis points increase from prior year. Operating Margin: 22.9% of sales, 100 basis points increase from prior year. Nutrition Sales Growth: 3.5% increase in the quarter. Diagnostics Sales Decline: 1.5% decrease, impacted by COVID testing sales decline and China procurement programs. EPD Sales Growth: Nearly 8% increase, surpassing $1 billion in quarterly sales. Medical Devices Sales Growth: 12% increase, driven by diabetes care, heart failure, structural heart, electrophysiology, and cardiac rhythm management. Diabetes Care Sales: $1.9 billion, 19.5% growth. Heart Failure Sales Growth: 14% increase in the quarter. Foreign Exchange Impact: Favorable 0.5% impact on second quarter sales. R&D and SG&A Expenses: Adjusted R&D at 6.3% of sales; adjusted SG&A at 27.7% of sales. Third Quarter EPS Forecast: $1.28 to $1.32. Warning! GuruFocus has detected 2 Warning Sign with WIT. Release Date: July 17, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Abbott Laboratories (NYSE:ABT) reported high single-digit sales growth and over 100 basis points of margin expansion in both gross and operating margins. The company achieved double-digit earnings per share growth, exceeding consensus estimates. Sales in the Nutrition segment increased by 3.5%, driven by strong demand for Ensure and Glucerna brands. Medical Devices sales grew by 12%, with significant contributions from diabetes care, heart failure, structural heart, electrophysiology, and cardiac rhythm management. Abbott Laboratories (NYSE:ABT) is making progress in its biosimilars portfolio, with 10 regulatory approval submissions completed and launches projected to begin in 2026. Negative Points Diagnostics sales declined by 1.5% due to a decrease in COVID testing sales and volume-based procurement programs in China, representing a significant headwind. The company faces challenges in the China Core Lab market, impacting overall sales growth. There are ongoing headwinds from COVID testing sales drop-off and changes in US funding for HIV testing. Abbott Laboratories (NYSE:ABT) is experiencing a $200 million impact from tariffs, which is affecting its financial performance. Foreign exchange remains a headwind on the bottom line, despite being neutral on the top line. Q & A Highlights Q: Can you provide context on Abbott's 2025 performance and the headwinds faced this year? A: Robert Ford, CEO, explained that Abbott's goal is to ensure each business meets and exceeds expectations. Despite challenges like the decline in COVID testing sales and issues in the China Core Lab market, Abbott is committed to high single-digit growth and double-digit EPS growth. The company is optimistic about 2026, with headwinds expected to be behind them and new product launches on the horizon. Q: What trends are you seeing in the Diabetes and Electrophysiology (EP) product lines? A: Robert Ford noted strong performance in both areas, with US Libre sales up nearly 26% and EP showing double-digit growth. In Diabetes, the Basal segment and non-insulin user segment are doing well, and the dual analyte sensor is expected to drive further growth. In EP, the launch of Volt internationally is progressing well, with positive feedback on its performance. Q: What is Abbott's reaction to the proposed competitive bidding for CGM and comments on wearables? A: Robert Ford stated that the CMS proposal for competitive bidding was expected and should not impact Abbott significantly. Regarding wearables, Ford emphasized their power in behavior modification and health improvement, aligning with Abbott's mission. He also confirmed that the dual ketone sensor could drive share gains in intensive insulin patients. Q: Can you provide an update on the CRM business and its growth trajectory? A: Robert Ford highlighted that the CRM business has shown sustainable growth, with AVEIR pacing systems driving this momentum. The business has seen increased physician training and implant rates, and Abbott plans to continue innovating with next-generation products and international expansion. Q: What are Abbott's plans for M&A, and how does it fit into the company's strategy? A: Robert Ford indicated that Abbott is focused on strategic M&A opportunities in diagnostics and devices, aiming for acquisitions that fit strategically and generate attractive returns. The company is selective due to its strong organic growth pipeline. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.